2026年3月3日，泰格医药集团旗下方达控股宣布已正式完成对观合医药的收购。此次收购将进一步完善 方达在全球中心实验室领域的布局，强化其在中国及亚太地区的综合服务能力。 观合医药是中国领先的临床研究实验室服务提供商，累计支持超过1,500项临床试验，覆盖多个治疗领 域。公司长期按照GCP规范开展运营，实验室通过CAP认证，同时获得NGSP Level 1实验室资质，并具 备放射性乙类工作场所资质。凭借成熟稳健的运营体系，观合医药持续为国内外制药企业和生物技术公 司提供符合国际监管要求、可支持审计的高质量实验室检测服务。在支持监管核查及新药注册申报方 面，公司积累了丰富经验，已助力50个新药成功获批上市。 收购完成后，方达控股将在中国进一步拓展中心实验室网络布局，提升对国内临床研究及多区域临床试 验（MRCT）的综合支持能力。通过整合观合医药在中心实验室领域的成熟运营经验，以及方达覆盖生 物分析、DMPK、安全性评价、CMC和临床研究支持等在内的一体化服务平台，方达将进一步提升端 到端研发服务能力，为全球制药企业、生物技术公司及科研机构提供更加高效、合规、协同的综合解决 方案。 方达控股相关负责人表示： "观合 ...

Core Insights - Fonda Holdings and GCCL signed a strategic memorandum of understanding (MOU) to enhance their influence in the global clinical trial market [1][3] - The collaboration aims to leverage both companies' service and laboratory network advantages to improve competitiveness in the US and Asia-Pacific regions [1][3] Company Overview - GCCL is a leading clinical trial sample analysis provider in South Korea, offering integrated "one-stop solutions" including central laboratories and bioanalytical laboratories [4] - Fonda Holdings is a comprehensive pharmaceutical R&D CRO with established centers in China, North America, and Europe, providing a wide range of outsourced R&D services [5] Strategic Collaboration - The partnership will explore joint clinical trial services, co-marketing, project support plans, and the development of new business opportunities [3] - Both companies will combine their regional expertise and global networks to execute clinical trial projects more efficiently and effectively [3] Leadership Statements - Fonda Holdings' Senior Vice President, Dr. Zhang Nan, emphasized the importance of this strategic cooperation in enhancing their influence in the Asia-Pacific market and providing faster, more efficient support for global clinical trials [3] - GCCL's CEO, KwanGoo Cho, highlighted the goal of creating new growth opportunities in the global clinical trial market by combining GCCL's strengths in bioanalysis and central laboratory services with Fonda's global capabilities [3]